AgPlenus Announces Reaching a 'Lead' Stage in its Novel Mode-of-Action Herbicide Program

Rhea-AI Summary

AgPlenus Ltd., a subsidiary of Evogene (NASDAQ: EVGN), has successfully reached the 'Lead' stage in its Mode-of-Action herbicide program with its candidate APH1. This milestone follows positive field tests indicating APH1 effectively controls resistant weeds, achieving 70%-100% control in 6 out of 9 commercial weed species. Notably, APH1 has shown efficacy against glyphosate-resistant strains and demonstrated crop selectivity. The development of this novel herbicide addresses critical herbicide resistance issues, with the global market for herbicides projected to hit $34 billion by 2022.

Positive

• APH1 reached the 'Lead' stage, indicating significant progress in herbicide development.
• Field tests showed 70%-100% efficacy against resistant weeds, confirming the herbicide's effectiveness.
• Demonstrated crop selectivity, indicating potential for safe application without harming crops.

Negative

• None.

REHOVOT, Israel, Dec. 15, 2020 /PRNewswire/ -- AgPlenus Ltd., an innovative company designing effective, sustainable crop protection products by leveraging computational biology and chemistry, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), announced today that it has reached the 'Lead' stage in its novel Mode-of-Action (MoA) herbicide program. The achievement of this milestone follows the conclusion of field tests that demonstrated that product candidate APH1, at commercial dose rates, effectively controlled a broad panel of weeds, including weeds that are known to have resistance to existing herbicides. These results were confirmed in independent field tests conducted by SynTech Research, an agricultural R&D contract research organization located in California.

For a short video clip of the field test, click here

Herbicide crop protection plays an important role in global food security with the global herbicide market estimated to reach $34 billion in 2022². Over the last several decades, the increasing use of existing MoA herbicides along with the extremely limited introduction of new MoA herbicides have resulted in weeds that are highly resistant to currently available commercial products. Herbicide resistance has become a critical issue for growers, reducing crop yields and requiring higher herbicide application rates. The key solution to the emergence of herbicide-resistance in weeds is the development and application of new MoA herbicides³.

AgPlenus' herbicide program focuses on the discovery and targeting of new MoAs to overcome herbicide resistance issues.  Herbicide candidate APH1 is the first chemical compound addressing a novel MoA from this program to reach the 'Lead' stage.

APH1 is a broad-spectrum herbicide candidate that has been shown to be effective against highly-resistant grass and broadleaf weeds. The positive results announced today, achieved in field tests in Israel and confirmed in independent field tests in California by SynTech Research, were conducted with commercial-level application rates on a broad panel of weeds in post-emergence application. Weed control was statistically significant (compared to untreated controls) and in the range of 70%-100% in 6 out of 9 commercially important weed species. Additionally, in greenhouse tests conducted in post-emergence applications, APH1 demonstrated efficacy against several key resistant weeds, including glyphosate⁴ resistant weed strains. In addition to efficacy against a broad panel of weed species, APH1 also exhibited crop selectivity; corn and cereals showed inherent tolerance to APH1. A patent application has been filed for this candidate.

These field tests followed a series of lab and greenhouse experiments. Lab experiments validated that the biological pathway that APH1 impacts in plants is a new MoA, not present in higher organisms such as mammals, which may impact its potential safety profile. Greenhouse experiments, conducted in varying pre- and post-emergence applications, demonstrated strong efficacy against weeds that are notorious for developing resistance.

The next steps in the further development of APH1 are expected to include field trials and safety studies to reach the stage of an 'Optimized Lead'.

Douglas Eisner, CEO of AgPlenus, stated: "I am happy to have joined AgPlenus at such a pivotal point in the development of its herbicide candidates. After years of computational and in-planta work, AgPlenus has achieved an important milestone that we will leverage to advance our herbicide program. No doubt, this is a testimony to the value computational approaches can bring to agriculture. We look forward to reporting future progress with APH1 and other product candidates."

Ofer Haviv, Chairman of AgPlenus and CEO of Evogene, stated: "I am excited to see AgPlenus achieve such a significant milestone in the development of one of the most desired products in crop protection – a new MoA herbicide. This is most certainly an outcome of AgPlenus' unique computational approach to crop protection development, based on the use of Evogene's ChemPass AI engine. I look forward to seeing the continued development of this product candidate and others in the coming year."

About a 'Lead' stage herbicide product candidate
The 'Lead' stage for a herbicide product candidate is achieved by demonstrating significant herbicidal efficacy, in field tests, at commercial application rates, on a broad panel of weeds.

About AgPlenus Ltd.
AgPlenus is designing effective and sustainable crop protection products by leveraging predictive biology and chemistry. The Company aims to develop crop protection products: herbicides, insecticides, fungicides and crop enhancers. AgPlenus has ongoing collaborations with industry leaders such as BASF and Corteva. AgPlenus is a subsidiary of Evogene Ltd. (NASDAQ: EVGN), (TASE: EVGN). For more information, please visit www.agplenus.com

About Evogene Ltd.:
Evogene (NASDAQ: EVGN) (TASE: EVGN) is a leading computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of our broadly applicable Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through the power of Big Data and Artificial Intelligence, has been designed to computationally discover and uniquely guide the development of life-science products based on microbes, small molecules and genetic elements. Utilizing the CPB platform, Evogene and its subsidiaries are now advancing product pipelines for human microbiome-based therapeutics through Biomica Ltd., medical cannabis through Canonic Ltd., ag-biologicals through Lavie Bio Ltd., ag-chemicals through AgPlenus Ltd., and ag-solutions for castor oil production through Casterra Ag Ltd. For more information, please visit www.evogene.com.

Forward Looking Statements
This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "could", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. For example, AgPlenus and Evogene are using forward-looking statements in this press release when they discuss the potential efficacy of APH1, the potential to receive a patent for APH1, the key solution to the emergence of herbicide resistance in weeds and the potential of APH1 to reach to the Optimized Lead stage. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene and its subsidiaries may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond the control of Evogene and its subsidiaries, including, without limitation, the global spread of COVID-19, or the Coronavirus, the various restrictions deriving therefrom and those risk factors contained in Evogene's reports filed with the applicable securities authorities. In addition, Evogene and its subsidiaries rely, and expect to continue to rely, on third parties to conduct certain activities, such as their field-trials and pre-clinical studies, and if these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines (including as a result of the effect of the Coronavirus), Evogene and its subsidiaries may experience significant delays in the conduct of their activities. Evogene and its subsidiaries disclaim any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

Evogene Investor Contact:	US Investor Relations:
Rivka Neufeld Investor Relations E: IR@evogene.com T: +972-8-931-1940	Joseph Green Edison Group E: jgreen@edisongroup.com T: +1 646-653-7030
	Laine Yonker Edison Group E: lyonker@edisongroup.com T: +1 646-653-7035

 

1. In previous publications, APH1 was referred to as HERB32
2. https://www.prnewswire.com/news-releases/global-3410-billion-herbicide-market-2022---research-and-markets-300458389.html
3. Green, Jerry M. and Owen, Micheal D. K. "Herbicide-Resistant Crops: Utilities and Limitations for Herbicide-Resistant Weed Management", J AgriCell Food Chem. 2011; 59(11); pp. 5819-5829. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3105486/.
4. Glyphosate is the active ingredient in one of the leading commercial products

View original content to download multimedia:http://www.prnewswire.com/news-releases/agplenus-announces-reaching-a-lead-stage-in-its-novel-mode-of-action-herbicide-program-301192730.html

SOURCE AgPlenus

FAQ

What is the significance of AgPlenus reaching the 'Lead' stage with APH1?

Reaching the 'Lead' stage signifies that APH1 has demonstrated effective weed control in field tests, an important milestone in herbicide development.

What was the efficacy of APH1 in field tests?

APH1 achieved 70%-100% control of a broad panel of resistant weeds, indicating its potential effectiveness in agricultural applications.

How does APH1 address weed resistance issues?

APH1 targets a novel Mode-of-Action, addressing the growing concern of herbicide resistance in weeds by providing an effective alternative.

What is the expected impact of AgPlenus's herbicide program on the market?

AgPlenus's program aims to introduce new herbicides to a market projected to reach $34 billion by 2022, crucial for global food security.